A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis
Latest Information Update: 21 May 2024
At a glance
- Drugs Fexofenadine (Primary)
- Indications Ragweed pollen hypersensitivity; Seasonal allergic rhinitis
- Focus Proof of concept; Therapeutic Use
- Acronyms FEXPRESAR
Most Recent Events
- 16 Nov 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2023 Planned End Date changed from 14 Mar 2023 to 14 Nov 2023.
- 06 Apr 2023 Planned primary completion date changed from 14 Mar 2023 to 14 Nov 2023.